Karin Jooss

Karin Jooss

Company: Gritstone bio

Job title: Head of Research & Development


Neoantigen Targeted Therapies in Combination with Immune Checkpoint Inhibitors: Learnings from Novel Clinical Data 3:30 pm

Heterologous prime/boost vaccination utilizing a Chimpanzee Adenoviral vector prime, and a self-amplifying RNA (samRNA) boost drives robust neoantigen specific T-cell responses Less is more: Lower doses of samRNA boost superior T-cell responses than high dose samRNA Neoantigen specific T-cell responses provide therapeutic benefit to patients with  advanced stage MSS-CRCRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.